risperidone has been researched along with Panic Disorder in 8 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "On the last-observation-carried forward analysis of repeated measures analysis of variance (ANOVA), risperidone was not more effective than placebo for the CGI-21 Anxiety score or the other anxiety outcome measures." | 9.14 | Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. ( Gonzalez, R; Harnett-Sheehan, K; Janavs, J; Keck, PE; McElroy, SL; Rogers, J; Sheehan, DV; Shivakumar, G; Suppes, T, 2009) |
| "Fifty six subjects with a history of panic attacks were randomized to receive either risperidone or paroxetine." | 9.14 | A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. ( Cohen, LJ; Galynker, II; Prosser, JM; Steele, A; Yard, S, 2009) |
| "Thirty patients with a primary diagnosis of an anxiety disorder-panic disorder (PD), social anxiety disorder (SAD), or generalized anxiety disorder (GAD)-refractory to initial pharmacotherapy with an adequate (or maximally tolerated) antidepressant and/or benzodiazepine trial of at least 8 weeks' duration prior to study initiation received open-label augmentation with flexibly dosed risperidone for 8 weeks." | 9.12 | An open-label trial of risperidone augmentation for refractory anxiety disorders. ( Christian, KM; Fischmann, D; Hoge, EA; Kinrys, G; Pollack, MH; Simon, NM; Worthington, JJ, 2006) |
| "On the last-observation-carried forward analysis of repeated measures analysis of variance (ANOVA), risperidone was not more effective than placebo for the CGI-21 Anxiety score or the other anxiety outcome measures." | 5.14 | Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. ( Gonzalez, R; Harnett-Sheehan, K; Janavs, J; Keck, PE; McElroy, SL; Rogers, J; Sheehan, DV; Shivakumar, G; Suppes, T, 2009) |
| "Fifty six subjects with a history of panic attacks were randomized to receive either risperidone or paroxetine." | 5.14 | A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. ( Cohen, LJ; Galynker, II; Prosser, JM; Steele, A; Yard, S, 2009) |
| "Thirty patients with a primary diagnosis of an anxiety disorder-panic disorder (PD), social anxiety disorder (SAD), or generalized anxiety disorder (GAD)-refractory to initial pharmacotherapy with an adequate (or maximally tolerated) antidepressant and/or benzodiazepine trial of at least 8 weeks' duration prior to study initiation received open-label augmentation with flexibly dosed risperidone for 8 weeks." | 5.12 | An open-label trial of risperidone augmentation for refractory anxiety disorders. ( Christian, KM; Fischmann, D; Hoge, EA; Kinrys, G; Pollack, MH; Simon, NM; Worthington, JJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Perna, G | 1 |
| Alessandra, A | 1 |
| Raffaele, B | 1 |
| Elisa, M | 1 |
| Giuseppina, D | 1 |
| Paolo, C | 1 |
| Maria, N | 1 |
| Daniela, C | 1 |
| Sheehan, DV | 2 |
| McElroy, SL | 2 |
| Harnett-Sheehan, K | 1 |
| Keck, PE | 1 |
| Janavs, J | 1 |
| Rogers, J | 1 |
| Gonzalez, R | 1 |
| Shivakumar, G | 1 |
| Suppes, T | 2 |
| Prosser, JM | 1 |
| Yard, S | 1 |
| Steele, A | 1 |
| Cohen, LJ | 1 |
| Galynker, II | 1 |
| Seo, JS | 1 |
| Jamieson, K | 1 |
| Cosgrove, V | 1 |
| Gwizdowski, IS | 1 |
| Yang, H | 1 |
| Rapinesi, C | 1 |
| Serata, D | 1 |
| Del Casale, A | 1 |
| Kotzalidis, GD | 1 |
| Romano, S | 1 |
| Milioni, M | 1 |
| Capezzuto, S | 1 |
| Carbonetti, P | 1 |
| Angeletti, G | 1 |
| Fensore, C | 1 |
| Tatarelli, R | 1 |
| Girardi, P | 1 |
| Simon, NM | 1 |
| Hoge, EA | 1 |
| Fischmann, D | 1 |
| Worthington, JJ | 1 |
| Christian, KM | 1 |
| Kinrys, G | 1 |
| Pollack, MH | 1 |
| Abraham, HD | 1 |
| Mamen, A | 1 |
| Takahashi, H | 1 |
| Higuchi, H | 1 |
| Shimizu, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder[NCT00277654] | Phase 3 | 111 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks[NCT00457106] | 90 participants (Anticipated) | Interventional | 2002-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for risperidone and Panic Disorder
| Article | Year |
|---|---|
Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines.
Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Panic Disorder; Piperazines; Quetiapine Fumarate; Ri | 2016 |
4 trials available for risperidone and Panic Disorder
| Article | Year |
|---|---|
Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anxiety; Anxiety Disorders; Bipolar Disorder; Comorbi | 2009 |
A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; | 2009 |
Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder.
Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Bipolar Disorder; Double-Blind Method; Female; Human | 2013 |
An open-label trial of risperidone augmentation for refractory anxiety disorders.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepi | 2006 |
3 other studies available for risperidone and Panic Disorder
| Article | Year |
|---|---|
Electroconvulsive therapy in a physically restrained man with comorbid major depression, severe agoraphobia with panic disorder, and histrionic personality disorder.
Topics: Adult; Agoraphobia; Antimanic Agents; Antipsychotic Agents; Depressive Disorder, Major; Electroconvu | 2012 |
LSD-like panic from risperidone in post-LSD visual disorder.
Topics: Adult; Antipsychotic Agents; Female; Hallucinations; Humans; Lysergic Acid Diethylamide; Male; Panic | 1996 |
Full remission of panic attacks in a schizophrenic patient after switching from haloperidol to risperidone.
Topics: Adult; Female; Haloperidol; Humans; Panic Disorder; Remission, Spontaneous; Risperidone; Schizophren | 2001 |